928 F.3d 1340
Fed. Cir.2019Background
- Enzo sued multiple diagnostics companies alleging patents covering non-radioactive labels attached to nucleotides (two patents: U.S. Pat. No. 6,992,180 and U.S. Pat. No. 8,097,405).
- The asserted claims cover broadly labeled oligo-/polynucleotides (ʼ180) and processes using such probes in situ or in liquid phase (ʼ405); claims require the probes to be hybridizable and detectable when hybridized.
- The patents claim labeling at phosphate (ʼ180) and at various nucleotide positions (ʼ405); specification provided sparse examples (notably Example V) and relied in part on prior work (Ward) for non-disruptive labeling positions.
- District court granted summary judgment that all asserted claims were invalid for lack of enablement (undue experimentation); Enzo appealed and the Federal Circuit consolidated the appeals.
- The Federal Circuit affirmed: because the claims require functional results (hybridizable + detectable) across a very large genus of embodiments and the specification lacks sufficient guidance/working examples, practicing the full claim scope would require undue experimentation.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Whether the specification enables the full scope of claims requiring probes that are hybridizable and detectable | Specification and Example V (plus ordinary skill) suffice to enable the claimed genus | Specification is too sparse, art was unpredictable, and many embodiments would require testing | Not enabled; summary judgment affirmed |
| Whether a single example (Example V) or prior art knowledge cures breadth | Example V and known Ward positions show labeled probes can work; skilled artisans could generalize | Example V is non-working/paper and prior art left serious doubts; cannot substitute for enabling disclosure | Example V insufficient; prior art knowledge not a substitute for enabling disclosure |
| Whether unpredictability of the field is relevant to enablement | Enzo: ordinary skill fills gaps; unpredictability was overcome by specification/prior art | Defendants: unpredictability means breadth of claims demands more disclosure; must test each embodiment | Unpredictability increases enablement burden; supports invalidity for undue experimentation |
| Whether enablement of narrower ʼ180 claims could support broader ʼ405 claims | Enzo: if ʼ180 enabled, the specification enables ʼ405 too | Defendants: ʼ405 is broader and likewise not enabled | ʼ405 also not enabled because it is broader and specification fails for ʼ180 |
Key Cases Cited
- Wyeth and Cordis Corp. v. Abbott Laboratories, 720 F.3d 1380 (Fed. Cir. 2013) (claims to a broad genus requiring functional screening held not enabled)
- In re Wands, 858 F.2d 731 (Fed. Cir. 1988) (factors for undue experimentation enablement inquiry)
- Alcon Research Ltd. v. Barr Labs., Inc., 745 F.3d 1180 (Fed. Cir. 2014) (clear-and-convincing standard and undue experimentation discussion)
- MagSil Corp. v. Hitachi Glob. Storage Techs., Inc., 687 F.3d 1377 (Fed. Cir. 2012) (specification must enable entire claim scope)
- Genentech, Inc. v. Novo Nordisk A/S, 108 F.3d 1361 (Fed. Cir. 1997) (well-known art cannot substitute for missing enabling disclosure)